Advocacy groups are pressing for an immediate update to India's National List of Essential Medicines (NLEM), which has not been revised since 2022. The inclusion of new cancer and diabetes drugs could impact public health access and expand price controls to these treatments.
Patient advocacy groups are calling for an urgent revision of India's National List of Essential Medicines (NLEM). The list, which currently includes 384 medicines, serves as a primary guide for government healthcare procurement and sets the ceiling for price controls on drugs sold in India. The current version was last updated in September 2022, and stakeholders argue that it no longer reflects the latest advancements in global medical standards.
The Working Group on Access to Medicines and Treatments has formally requested the Indian Council of Medical Research to include several critical therapies that are currently omitted. Specifically, the groups are seeking the addition of 17 active cancer-treating agents and four supportive medications. Among the requested drugs are Bevacizumab, Cladribine, Dasatinib, Erlotinib, and Ibrutinib. Additionally, the proposal includes the integration of nine monoclonal antibodies, such as Adalimumab, which are widely used for various chronic and complex conditions.
Impact on Drug Pricing and Market Access
For investors and the healthcare sector, the NLEM is a significant regulatory tool because drugs included in this list are subject to price regulation by the National Pharmaceutical Pricing Authority (NPPA). When a drug is added to the NLEM, its maximum retail price is typically capped, which often leads to lower margins for manufacturers but can drive higher sales volumes due to increased accessibility in both government hospitals and private pharmacies.
The push for an update is largely motivated by the gap between India's current list and the World Health Organization's (WHO) model list, which has been updated twice since 2022 and now covers 523 medicines. Advocacy groups suggest that aligning the Indian list with these global benchmarks would improve health equity and broaden the availability of affordable, high-quality treatments.
Next Steps for Policy and Industry
If the government decides to initiate an update to the NLEM, the process will involve extensive consultations with health experts, medical associations, and pharmaceutical industry representatives. Any potential expansion of the list could influence the revenue models of companies involved in the production of these high-value oncology and specialty drugs. Investors and industry analysts will be monitoring official communications from the Ministry of Health and the Indian Council of Medical Research to see if a formal review committee is established. The timeline for such revisions often spans several months, as the government must balance the goals of affordability for patients with the need to maintain a sustainable environment for drug innovation and supply.